Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Aclidinium Bromide Post-Authorisation Safety Study to Evaluate the Risk of Cardiovascular Endpoints: Common Study Protocol

Trial Profile

Aclidinium Bromide Post-Authorisation Safety Study to Evaluate the Risk of Cardiovascular Endpoints: Common Study Protocol

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 01 Nov 2018

At a glance

  • Drugs Aclidinium bromide (Primary) ; Aclidinium bromide/formoterol; Beclometasone/formoterol; Budesonide/formoterol; Formoterol/fluticasone propionate; Formoterol/glycopyrrolate; Glycopyrrolate; Glycopyrrolate/indacaterol; Mometasone/formoterol; Olodaterol/tiotropium bromide; Salmeterol/fluticasone propionate; Tiotropium bromide; Umeclidinium; Umeclidinium/vilanterol
  • Indications Chronic obstructive pulmonary disease
  • Focus Adverse reactions
  • Acronyms PASS
  • Sponsors AstraZeneca
  • Most Recent Events

    • 24 Oct 2018 Planned End Date changed from 30 Jun 2023 to 31 Dec 2022.
    • 24 Oct 2018 Status changed from completed to active, no longer recruiting.
    • 31 Aug 2018 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top